Abstract
Belantamab Mafodotin (B, GSK2857916) is an antibody drug conjugate targeting BCMA. In the first-in-human clinical trial, a response rate of 60% and median progression free survival of 12 months was demonstrated for patients with relapsed/ refractory myeloma (MM). Blurring of vision and thrombocytopenia were the most significant toxicities requiring dose reduction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
